Sareum Hldgs Plc (SAR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sareum Hldgs Plc (SAR) has a cash flow conversion efficiency ratio of -0.763x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (£-1.74 Million ≈ $-2.33 Million USD) by net assets (£2.28 Million ≈ $3.06 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sareum Hldgs Plc - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Sareum Hldgs Plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Sareum Hldgs Plc carry for a breakdown of total debt and financial obligations.
Sareum Hldgs Plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sareum Hldgs Plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cubic Digital Technology Co Ltd
SHE:300344
|
-0.061x |
|
TT Vision Holdings Berhad
KLSE:0272
|
-0.018x |
|
Rimfire Pacific Mining Ltd
AU:RIM
|
-0.126x |
|
DRC Systems India Limited
NSE:DRCSYSTEMS
|
0.019x |
|
Hawthorn Resources Ltd
AU:HAW
|
-0.019x |
|
Philippos Nakas S.A
AT:NAKAS
|
0.086x |
|
MMC Sanayi ve Ticari Yatirimlar AS
IS:MMCAS
|
0.001x |
|
Siab Holdings Bhd
KLSE:0241
|
-0.188x |
Annual Cash Flow Conversion Efficiency for Sareum Hldgs Plc (2004–2025)
The table below shows the annual cash flow conversion efficiency of Sareum Hldgs Plc from 2004 to 2025. For the full company profile with market capitalisation and key ratios, see Sareum Hldgs Plc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | £2.28 Million ≈ $3.06 Million |
£-2.55 Million ≈ $-3.43 Million |
-1.120x | +39.57% |
| 2024-06-30 | £2.11 Million ≈ $2.84 Million |
£-3.92 Million ≈ $-5.26 Million |
-1.854x | +34.57% |
| 2023-06-30 | £1.15 Million ≈ $1.55 Million |
£-3.27 Million ≈ $-4.39 Million |
-2.833x | -475.87% |
| 2022-06-30 | £4.33 Million ≈ $5.82 Million |
£-2.13 Million ≈ $-2.86 Million |
-0.492x | +12.44% |
| 2021-06-30 | £2.80 Million ≈ $3.75 Million |
£-1.57 Million ≈ $-2.11 Million |
-0.562x | -24.65% |
| 2020-06-30 | £1.80 Million ≈ $2.42 Million |
£-813.09K ≈ $-1.09 Million |
-0.451x | +60.95% |
| 2019-06-30 | £1.09 Million ≈ $1.47 Million |
£-1.26 Million ≈ $-1.70 Million |
-1.154x | -18.37% |
| 2018-06-30 | £1.63 Million ≈ $2.19 Million |
£-1.59 Million ≈ $-2.14 Million |
-0.975x | -371.10% |
| 2017-06-30 | £2.35 Million ≈ $3.15 Million |
£843.87K ≈ $1.13 Million |
0.360x | +198.88% |
| 2016-06-30 | £1.86 Million ≈ $2.50 Million |
£-678.00K ≈ $-910.50K |
-0.364x | -5.22% |
| 2015-06-30 | £1.86 Million ≈ $2.50 Million |
£-644.24K ≈ $-865.15K |
-0.346x | +24.16% |
| 2014-06-30 | £1.72 Million ≈ $2.31 Million |
£-785.34K ≈ $-1.05 Million |
-0.456x | +65.64% |
| 2013-06-30 | £439.10K ≈ $589.67K |
£-582.74K ≈ $-782.57K |
-1.327x | -5.88% |
| 2012-06-30 | £480.38K ≈ $645.10K |
£-602.14K ≈ $-808.62K |
-1.253x | -100.37% |
| 2011-06-30 | £876.00K ≈ $1.18 Million |
£-548.00K ≈ $-735.91K |
-0.626x | +37.68% |
| 2010-06-30 | £523.00K ≈ $702.34K |
£-525.00K ≈ $-705.03K |
-1.004x | +54.03% |
| 2009-06-30 | £327.00K ≈ $439.13K |
£-714.00K ≈ $-958.84K |
-2.183x | -81.42% |
| 2008-06-30 | £1.40 Million ≈ $1.88 Million |
£-1.69 Million ≈ $-2.26 Million |
-1.204x | -579.37% |
| 2007-06-30 | £1.37 Million ≈ $1.83 Million |
£-242.00K ≈ $-324.98K |
-0.177x | +13.59% |
| 2006-06-30 | £1.20 Million ≈ $1.60 Million |
£-245.00K ≈ $-329.01K |
-0.205x | +82.42% |
| 2005-06-30 | £1.32 Million ≈ $1.77 Million |
£-1.54 Million ≈ $-2.07 Million |
-1.166x | -2128.90% |
| 2004-06-30 | £-87.00K ≈ $-116.83K |
£-5.00K ≈ $-6.71K |
0.057x | -- |
About Sareum Hldgs Plc
Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases. It also develops SDC-1802, a TYK2/JAK1 inhibitor, that is in preclinical st… Read more